Comparison of efficacy of topical janus kinase inhibitor tofacitinib used alone versus used in combination with targeted narrow-band ultraviolet b (excimer) therapy

Abstract

ABSTRACT BACKGROUND A chronic skin disorder which occurs due to loss of melanocytes and manifests with patches of depigmentation is categorized as vitiligo. Despite various treatment modalities, including corticosteroids and phototherapy, no definitive cure exists. Recent advances highlight that Janus Kinase inhibitors such as Tofacitinib play a role in regulating the immune mechanism associated with the pathogenesis of vitiligo. Hence, this study was undertaken. to compare the effectiveness of topical Tofacitinib alone versus its combination with narrowband ultraviolet B (NBUVB) therapy. AIMS AND OBJECTIVES To compare the effectiveness of topical JAK inhibitor (Tofacitinib) alone versus used along with concomitant phototherapy on de-pigmented lesions of vitiligo and to determine the effect of topical JAK inhibitor (Tofacitinib) on pigmentation in vitiligo lesions.